We analyzed HER2-low breast cancer in our cohort and found that the expression of cGAS-STING and immune cell infiltration did not differ between HER2-0 and HER2-low patients (Supplementary Fig. 6). This evidence concerns the gene ERBB2 and breast carcinoma.